Search

Your search keyword '"Bonifacio M"' showing total 487 results
Start Over Author "Bonifacio M"
487 results on '"Bonifacio M"'

2. BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study

Author

Malfona, F., Tanasi, I., Piccini, M., Papayannidis, C., Federico, V., Mancini, V., Roncoroni, E., Todisco, E., Bianchi, S., Ciotti, G., Chiusolo, Patrizia, Gentile, M., Gianfelici, V., Giglio, F., Malagola, M., Mule, A., Saraceni, F., Vetro, C., Zallio, F., Cappelli, L. V., Pizzolo, G., Foa, Robin, Bonifacio, M., Chiaretti, S., Chiusolo P. (ORCID:0000-0002-1355-1587), Foa R., Malfona, F., Tanasi, I., Piccini, M., Papayannidis, C., Federico, V., Mancini, V., Roncoroni, E., Todisco, E., Bianchi, S., Ciotti, G., Chiusolo, Patrizia, Gentile, M., Gianfelici, V., Giglio, F., Malagola, M., Mule, A., Saraceni, F., Vetro, C., Zallio, F., Cappelli, L. V., Pizzolo, G., Foa, Robin, Bonifacio, M., Chiaretti, S., Chiusolo P. (ORCID:0000-0002-1355-1587), and Foa R.

Abstract

N/A

Published
2024

4. MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia

Author

Mazzera, L, Abeltino, M, Lombardi, G, Cantoni, A, Jottini, S, Corradi, A, Ricca, M, Rossetti, E, Armando, F, Peli, A, Ferrari, A, Martinelli, G, Scupoli, M, Visco, C, Bonifacio, M, Ripamonti, A, Gambacorti-Passerini, C, Bonati, A, Perris, R, Lunghi, P, Mazzera L., Abeltino M., Lombardi G., Cantoni A. M., Jottini S., Corradi A., Ricca M., Rossetti E., Armando F., Peli A., Ferrari A., Martinelli G., Scupoli M. T., Visco C., Bonifacio M., Ripamonti A., Gambacorti-Passerini C., Bonati A., Perris R., Lunghi P., Mazzera, L, Abeltino, M, Lombardi, G, Cantoni, A, Jottini, S, Corradi, A, Ricca, M, Rossetti, E, Armando, F, Peli, A, Ferrari, A, Martinelli, G, Scupoli, M, Visco, C, Bonifacio, M, Ripamonti, A, Gambacorti-Passerini, C, Bonati, A, Perris, R, Lunghi, P, Mazzera L., Abeltino M., Lombardi G., Cantoni A. M., Jottini S., Corradi A., Ricca M., Rossetti E., Armando F., Peli A., Ferrari A., Martinelli G., Scupoli M. T., Visco C., Bonifacio M., Ripamonti A., Gambacorti-Passerini C., Bonati A., Perris R., and Lunghi P.

Abstract

Resistance to tyrosine kinase inhibitors (TKIs) remains a clinical challenge in Ph-positive variants of chronic myeloid leukemia. We provide mechanistic insights into a previously undisclosed MEK1/2/BCR::ABL1/BCR/ABL1-driven signaling loop that may determine the efficacy of arsenic trioxide (ATO) in TKI-resistant leukemic patients. We find that activated MEK1/2 assemble into a pentameric complex with BCR::ABL1, BCR and ABL1 to induce phosphorylation of BCR and BCR::ABL1 at Tyr360 and Tyr177, and ABL1, at Thr735 and Tyr412 residues thus provoking loss of BCR’s tumor-suppression functions, enhanced oncogenic activity of BCR::ABL1, cytoplasmic retention of ABL1 and consequently drug resistance. Coherently, pharmacological blockade of MEK1/2 induces dissociation of the pentameric MEK1/2/BCR::ABL1/BCR/ABL1 complex and causes a concurrent BCRY360/Y177, BCR::ABL1Y360/Y177 and cytoplasmic ABL1Y412/T735 dephosphorylation thereby provoking the rescue of the BCR’s anti-oncogenic activities, nuclear accumulation of ABL1 with tumor-suppressive functions and consequently, growth inhibition of the leukemic cells and an ATO sensitization via BCR-MYC and ABL1-p73 signaling axes activation. Additionally, the allosteric activation of nuclear ABL1 was consistently found to enhance the anti-leukemic effects of the MEK1/2 inhibitor Mirdametinib, which when combined with ATO, significantly prolonged the survival of mice bearing BCR::ABL1-T315I-induced leukemia. These findings highlight the therapeutic potential of MEK1/2-inhibitors/ATO combination for the treatment of TKI-resistant leukemia. [Figure not available: see fulltext.].

Published
2023

5. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study

Author

Cerrano, M, Bonifacio, M, Olivi, M, Curti, A, Malagola, M, Dargenio, M, Scattolin, A, Papayannidis, C, Forghieri, F, Gurrieri, C, Tanasi, I, Zappasodi, P, Starza, R, Fracchiolla, N, Chiusolo, P, Giaccone, L, Del Principe, M, Giglio, F, Defina, M, Favre, C, Rizzari, C, Castella, B, Pizzolo, G, Ferrara, F, Chiaretti, S, Foa, R, Cerrano M., Bonifacio M., Olivi M., Curti A., Malagola M., Dargenio M., Scattolin A. M., Papayannidis C., Forghieri F., Gurrieri C., Tanasi I., Zappasodi P., Starza R. L., Fracchiolla N. S., Chiusolo P., Giaccone L., Del Principe M. I., Giglio F., Defina M., Favre C., Rizzari C., Castella B., Pizzolo G., Ferrara F., Chiaretti S., Foa R., Cerrano, M, Bonifacio, M, Olivi, M, Curti, A, Malagola, M, Dargenio, M, Scattolin, A, Papayannidis, C, Forghieri, F, Gurrieri, C, Tanasi, I, Zappasodi, P, Starza, R, Fracchiolla, N, Chiusolo, P, Giaccone, L, Del Principe, M, Giglio, F, Defina, M, Favre, C, Rizzari, C, Castella, B, Pizzolo, G, Ferrara, F, Chiaretti, S, Foa, R, Cerrano M., Bonifacio M., Olivi M., Curti A., Malagola M., Dargenio M., Scattolin A. M., Papayannidis C., Forghieri F., Gurrieri C., Tanasi I., Zappasodi P., Starza R. L., Fracchiolla N. S., Chiusolo P., Giaccone L., Del Principe M. I., Giglio F., Defina M., Favre C., Rizzari C., Castella B., Pizzolo G., Ferrara F., Chiaretti S., and Foa R.

Published
2022

6. Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study

Author

Elli, E, Di Veroli, A, Bartoletti, D, Iurlo, A, Carmosino, I, Benevolo, G, Abruzzese, E, Bonifacio, M, Bergamaschi, M, Polverelli, N, Caramella, M, Cilloni, D, Tiribelli, M, Pugliese, N, Caocci, G, Crisa, E, Porrini, R, Markovic, U, Renso, R, Auteri, G, Cattaneo, D, Trawinska, M, Scaffidi, L, Biale, L, Bucelli, C, Breccia, M, Gambacorti Passerini, C, Palumbo, G, Latagliata, R, Palandri, F, Elli E. M., Di Veroli A., Bartoletti D., Iurlo A., Carmosino I., Benevolo G., Abruzzese E., Bonifacio M., Bergamaschi M., Polverelli N., Caramella M., Cilloni D., Tiribelli M., Pugliese N., Caocci G., Crisa E., Porrini R., Markovic U., Renso R., Auteri G., Cattaneo D., Trawinska M. M., Scaffidi L., Biale L., Bucelli C., Breccia M., Gambacorti Passerini C., Palumbo G. A., Latagliata R., Palandri F., Elli, E, Di Veroli, A, Bartoletti, D, Iurlo, A, Carmosino, I, Benevolo, G, Abruzzese, E, Bonifacio, M, Bergamaschi, M, Polverelli, N, Caramella, M, Cilloni, D, Tiribelli, M, Pugliese, N, Caocci, G, Crisa, E, Porrini, R, Markovic, U, Renso, R, Auteri, G, Cattaneo, D, Trawinska, M, Scaffidi, L, Biale, L, Bucelli, C, Breccia, M, Gambacorti Passerini, C, Palumbo, G, Latagliata, R, Palandri, F, Elli E. M., Di Veroli A., Bartoletti D., Iurlo A., Carmosino I., Benevolo G., Abruzzese E., Bonifacio M., Bergamaschi M., Polverelli N., Caramella M., Cilloni D., Tiribelli M., Pugliese N., Caocci G., Crisa E., Porrini R., Markovic U., Renso R., Auteri G., Cattaneo D., Trawinska M. M., Scaffidi L., Biale L., Bucelli C., Breccia M., Gambacorti Passerini C., Palumbo G. A., Latagliata R., and Palandri F.

Abstract

Deferasirox (DFX) is used for the management of iron overload (IOL) in many haematological malignancies including myelofibrosis (MF). The ‘RUX-IOL’ study retrospectively collected 69 MF patients treated with ruxolitinib (RUX) and DFX for IOL to assess: safety, efficacy in term of iron chelation response (ICR) and erythroid response (ER), and impact on overall survival of the combination therapy. The RUX–DFX therapy was administered for a median time of 12.4 months (interquartile range 3.1–71.2). During treatment, 36 (52.2%) and 34 (49.3%) patients required RUX and DFX dose reductions, while eight (11.6%) and nine (13.1%) patients discontinued due to RUX- or DFX-related adverse events; no unexpected toxicity was reported. ICR and ER were achieved by 33 (47.8%) and 32 patients (46.4%) respectively. Thirteen (18.9%) patients became transfusion-independent. Median time to ICR and ER was 6.2 and 2 months respectively. Patients achieving an ER were more likely to obtain an ICR also (p = 0.04). In multivariable analysis, the absence of leukocytosis at baseline (p = 0.02) and achievement of an ICR at any time (p = 0.02) predicted improved survival. In many MF patients, the RUX–DFX combination provided ICR and ER responses that correlated with improved outcome in the absence of unexpected toxicities. This strategy deserves further clinical investigation.

Published
2022

7. Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML

Author

Tiribelli, M., Latagliata, R., Breccia, M., Capodanno, I., Miggiano, M. C., Cavazzini, F., Bucelli, C., Attolico, I., Crescenzi, S. L., Russo, S., Annunziata, M., Sora', Federica, Bonifacio, M., Mulas, O., Loglisci, G., Maggi, A., Binotto, G., Crisa, E., Scortechini, A. R., Leporace, A. P., Sancetta, R., Murgano, P., Abruzzese, E., Stagno, F., Rapezzi, D., Luzi, D., Vincelli, I., Bocchia, M., Fava, C., Malato, A., Crugnola, M., Pizzuti, M., Lunghi, F., Galimberti, S., Dalmazzo, M., Fanin, R., Scalzulli, E., Foa, R., Iurlo, A., Saglio, G., Specchia, G., Sora' F. (ORCID:0000-0002-9607-5298), Tiribelli, M., Latagliata, R., Breccia, M., Capodanno, I., Miggiano, M. C., Cavazzini, F., Bucelli, C., Attolico, I., Crescenzi, S. L., Russo, S., Annunziata, M., Sora', Federica, Bonifacio, M., Mulas, O., Loglisci, G., Maggi, A., Binotto, G., Crisa, E., Scortechini, A. R., Leporace, A. P., Sancetta, R., Murgano, P., Abruzzese, E., Stagno, F., Rapezzi, D., Luzi, D., Vincelli, I., Bocchia, M., Fava, C., Malato, A., Crugnola, M., Pizzuti, M., Lunghi, F., Galimberti, S., Dalmazzo, M., Fanin, R., Scalzulli, E., Foa, R., Iurlo, A., Saglio, G., Specchia, G., and Sora' F. (ORCID:0000-0002-9607-5298)

Abstract

Background: Imatinib, dasatinib, and nilotinib are tyrosine kinase inhibitors (TKIs) approved in Italy for frontline treatment of chronic-phase chronic myeloid leukemia (CP-CML). The choice of TKI is based on a combined evaluation of the patient’s and the disease characteristics. The aim of this study was to analyze the use of frontline TKI therapy in an unselected cohort of Italian patients with CP-CML to correlate the choice with the patient’s features. Methods: A total of 1967 patients with CP-CML diagnosed between 2012 and 2019 at 36 centers throughout Italy were retrospectively evaluated; 1089 patients (55.4%) received imatinib and 878 patients (44.6%) received a second-generation (2G) TKI. Results: Second-generation TKIs were chosen for most patients aged <45 years (69.2%), whereas imatinib was used in 76.7% of patients aged >65 years (p <.001). There was a predominant use of imatinib in intermediate/high European long–term survival risk patients (60.0%/66.0% vs. 49.7% in low-risk patients) and a limited use of 2G-TKIs in patients with comorbidities such as hypertension, diabetes, chronic obstructive pulmonary disease, previous neoplasms, ischemic heart disease, or stroke and in those with >3 concomitant drugs. We observed a greater use of imatinib (61.1%) in patients diagnosed in 2018–2019 compared to 2012–2017 (53.2%; p =.002). In multivariable analysis, factors correlated with imatinib use were age > 65 years, spleen size, the presence of comorbidities, and ≥3 concomitant medications. Conclusions: This observational study of almost 2000 cases of CML shows that imatinib is the frontline drug of choice in 55% of Italian patients with CP-CML, with 2G-TKIs prevalently used in younger patients and in those with no concomitant clinical conditions. Introduction of the generic formulation in 2018 seems to have fostered imatinib use.

Published
2023

8. The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis

Author

Mannelli, F., Crupi, F., Zanotti, R., Pagano, Livio, Rapezzi, D., Tanasi, I., Criscuolo, Marianna, Bonifacio, M., Fresa, Alberto, Guglielmelli, P., Vannucchi, A. M., Pagano L. (ORCID:0000-0001-8287-928X), Criscuolo M., Fresa A., Mannelli, F., Crupi, F., Zanotti, R., Pagano, Livio, Rapezzi, D., Tanasi, I., Criscuolo, Marianna, Bonifacio, M., Fresa, Alberto, Guglielmelli, P., Vannucchi, A. M., Pagano L. (ORCID:0000-0001-8287-928X), Criscuolo M., and Fresa A.

Abstract

In systemic mastocytosis, cytoreductive treatment is indicated for advanced systemic mastocytosis (AdvSM) variants. The treatment scenario is rapidly diversifying especially with the introduction of KIT tyrosine kinase inhibitors. Avapritinib is a second-generation potent and selective inhibitor of the mutant KIT D816V that, based on the results of pivotal clinical trials, was approved for the treatment of adults with AdvSM by the regulatory agencies US FDA and EMA. The present article reports the experience of treating SM patients with avapritinib in an Italian compassionate use program. The data from our case series confirm the drug as being active after multiple lines of treatment allowing rapid achievement of profound responses, making it also an effective bridging strategy to allogeneic transplant in eligible patients. However, the anticipated wider use of avapritinib in the near future will require careful monitoring of side effects, especially in heavily pretreated patients.

Published
2023

9. Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia–like or acute lymphoblastic leukemia–like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study

Author

Lazzarotto, D., Tanasi, I., Vitale, A., Piccini, M., Dargenio, M., Giglio, F., Forghieri, F., Fracchiolla, N., Cerrano, M., Todisco, E., Papayannidis, C., Leoncin, M., Defina, M., Guolo, F., Pasciolla, C., Delia, M., Chiusolo, Patrizia, Mule, A., Candoni, A., Bonifacio, M., Pizzolo, G., Foa, R., Chiusolo P. (ORCID:0000-0002-1355-1587), Lazzarotto, D., Tanasi, I., Vitale, A., Piccini, M., Dargenio, M., Giglio, F., Forghieri, F., Fracchiolla, N., Cerrano, M., Todisco, E., Papayannidis, C., Leoncin, M., Defina, M., Guolo, F., Pasciolla, C., Delia, M., Chiusolo, Patrizia, Mule, A., Candoni, A., Bonifacio, M., Pizzolo, G., Foa, R., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

Mixed-phenotype acute leukemia (MPAL) is a rare disease. Treatment is often similar to that of acute lymphoblastic leukemia (ALL), but the outcome in adults and the role of allogeneic stem cell transplantation (AlloSCT) are not well defined. We report on 77 adult patients diagnosed with MPAL over the last 10 years and treated with a curative intent. Median age was 49 years; 7.6% of cases had a BCR::ABL1 rearrangement. Thirty patients (39%) were treated with an acute myeloid leukemia (AML)–like induction and 47 (61%) with an ALL-like scheme. The complete remission (CR) rate was 67.6% and an ALL-like therapy was associated with a better CR rate (P = 0.048). The median OS was 41.9 months; age ≤ 60 years was associated with a better OS (67 vs 26 months, P = 0.014). An AlloSCT was performed in 50 patients (65%). The 5-year OS of transplanted patients was 54%. The OS post-AlloSCT was better in patients who were minimal residual disease (MRD)-negative prior to transplant (75.8% vs 45.2%, P = 0.06). This study shows that MPAL patients respond better to an ALL-like induction therapy; that consolidation therapy should include, whenever possible, an AlloSCT and that MRD negativity should be a primary endpoint of treatment.

Published
2023

10. The biogeography of the Amazonian tree flora

Author

Bruno Garcia Luize, Hanna Tuomisto, Robin Ekelschot, Kyle G. Dexter, Iêda L. do Amaral, Luiz de Souza Coelho, Francisca Dionízia de Almeida Matos, Diógenes de Andrade Lima Filho, Rafael P. Salomão, Florian Wittmann, Carolina V. Castilho, Marcelo de Jesus Veiga Carim, Juan Ernesto Guevara, Oliver L. Phillips, William E. Magnusson, Daniel Sabatier, Juan David Cardenas Revilla, Jean-François Molino, Mariana Victória Irume, Maria Pires Martins, José Renan da Silva Guimarães, José Ferreira Ramos, Olaf S. Bánki, Maria Teresa Fernandez Piedade, Dairon Cárdenas López, Nigel C. A. Pitman, Layon O. Demarchi, Jochen Schöngart, Evlyn Márcia Moraes de Leão Novo, Percy Núñez Vargas, Thiago Sanna Freire Silva, Eduardo Martins Venticinque, Angelo Gilberto Manzatto, Neidiane Farias Costa Reis, John Terborgh, Katia Regina Casula, Euridice N. Honorio Coronado, Abel Monteagudo Mendoza, Juan Carlos Montero, Flávia R. C. Costa, Ted R. Feldpausch, Adriano Costa Quaresma, Nicolás Castaño Arboleda, Charles Eugene Zartman, Timothy J. Killeen, Beatriz S. Marimon, Ben Hur Marimon, Rodolfo Vasquez, Bonifacio Mostacedo, Rafael L. Assis, Chris Baraloto, Dário Dantas do Amaral, Julien Engel, Pascal Petronelli, Hernán Castellanos, Marcelo Brilhante de Medeiros, Marcelo Fragomeni Simon, Ana Andrade, José Luís Camargo, William F. Laurance, Susan G. W. Laurance, Lorena Maniguaje Rincón, Juliana Schietti, Thaiane R. Sousa, Gisele Biem Mori, Emanuelle de Sousa Farias, Maria Aparecida Lopes, José Leonardo Lima Magalhães, Henrique Eduardo Mendonça Nascimento, Helder Lima de Queiroz, Caroline C. Vasconcelos, Gerardo A. Aymard C, Roel Brienen, Pablo R. Stevenson, Alejandro Araujo-Murakami, Bruno Barçante Ladvocat Cintra, Tim R. Baker, Yuri Oliveira Feitosa, Hugo F. Mogollón, Joost F. Duivenvoorden, Carlos A. Peres, Miles R. Silman, Leandro Valle Ferreira, José Rafael Lozada, James A. Comiskey, José Julio de Toledo, Gabriel Damasco, Nállarett Dávila, Freddie C. Draper, Roosevelt García-Villacorta, Aline Lopes, Alberto Vicentini, Fernando Cornejo Valverde, Alfonso Alonso, Luzmila Arroyo, Francisco Dallmeier, Vitor H. F. Gomes, Eliana M. Jimenez, David Neill, Maria Cristina Peñuela Mora, Janaína Costa Noronha, Daniel P. P. de Aguiar, Flávia Rodrigues Barbosa, Yennie K. Bredin, Rainiellen de Sá Carpanedo, Fernanda Antunes Carvalho, Fernanda Coelho de Souza, Kenneth J. Feeley, Rogerio Gribel, Torbjørn Haugaasen, Joseph E. Hawes, Marcelo Petratti Pansonato, John J. Pipoly, Marcos Ríos Paredes, Domingos de Jesus Rodrigues, Jos Barlow, Erika Berenguer, Izaias Brasil da Silva, Maria Julia Ferreira, Joice Ferreira, Paul V. A. Fine, Marcelino Carneiro Guedes, Carolina Levis, Juan Carlos Licona, Boris Eduardo Villa Zegarra, Vincent Antoine Vos, Carlos Cerón, Flávia Machado Durgante, Émile Fonty, Terry W. Henkel, John Ethan Householder, Isau Huamantupa-Chuquimaco, Marcos Silveira, Juliana Stropp, Raquel Thomas, Doug Daly, William Milliken, Guido Pardo Molina, Toby Pennington, Ima Célia Guimarães Vieira, Bianca Weiss Albuquerque, Wegliane Campelo, Alfredo Fuentes, Bente Klitgaard, José Luis Marcelo Pena, J. Sebastián Tello, Corine Vriesendorp, Jerome Chave, Anthony Di Fiore, Renato Richard Hilário, Luciana de Oliveira Pereira, Juan Fernando Phillips, Gonzalo Rivas-Torres, Tinde R. van Andel, Patricio von Hildebrand, William Balee, Edelcilio Marques Barbosa, Luiz Carlos de Matos Bonates, Hilda Paulette Dávila Doza, Ricardo Zárate Gómez, Therany Gonzales, George Pepe Gallardo Gonzales, Bruce Hoffman, André Braga Junqueira, Yadvinder Malhi, Ires Paula de Andrade Miranda, Linder Felipe Mozombite Pinto, Adriana Prieto, Agustín Rudas, Ademir R. Ruschel, Natalino Silva, César I. A. Vela, Stanford Zent, Egleé L. Zent, María José Endara, Angela Cano, Yrma Andreina Carrero Márquez, Diego F. Correa, Janaina Barbosa Pedrosa Costa, Bernardo Monteiro Flores, David Galbraith, Milena Holmgren, Michelle Kalamandeen, Guilherme Lobo, Luis Torres Montenegro, Marcelo Trindade Nascimento, Alexandre A. Oliveira, Maihyra Marina Pombo, Hirma Ramirez-Angulo, Maira Rocha, Veridiana Vizoni Scudeller, Maria Natalia Umaña, Geertje van der Heijden, Emilio Vilanova Torre, Tony Mori Vargas, Manuel Augusto Ahuite Reategui, Cláudia Baider, Henrik Balslev, Sasha Cárdenas, Luisa Fernanda Casas, William Farfan-Rios, Cid Ferreira, Reynaldo Linares-Palomino, Casimiro Mendoza, Italo Mesones, Germaine Alexander Parada, Armando Torres-Lezama, Ligia Estela Urrego Giraldo, Daniel Villarroel, Roderick Zagt, Miguel N. Alexiades, Edmar Almeida de Oliveira, Riley P. Fortier, Karina Garcia-Cabrera, Lionel Hernandez, Walter Palacios Cuenca, Susamar Pansini, Daniela Pauletto, Freddy Ramirez Arevalo, Adeilza Felipe Sampaio, Elvis H. Valderrama Sandoval, Luis Valenzuela Gamarra, Marina Hirota, Clarisse Palma-Silva, and Hans ter Steege

Subjects
Biology (General), QH301-705.5
Abstract

Abstract We describe the geographical variation in tree species composition across Amazonian forests and show how environmental conditions are associated with species turnover. Our analyses are based on 2023 forest inventory plots (1 ha) that provide abundance data for a total of 5188 tree species. Within-plot species composition reflected both local environmental conditions (especially soil nutrients and hydrology) and geographical regions. A broader-scale view of species turnover was obtained by interpolating the relative tree species abundances over Amazonia into 47,441 0.1-degree grid cells. Two main dimensions of spatial change in tree species composition were identified. The first was a gradient between western Amazonia at the Andean forelands (with young geology and relatively nutrient-rich soils) and central–eastern Amazonia associated with the Guiana and Brazilian Shields (with more ancient geology and poor soils). The second gradient was between the wet forests of the northwest and the drier forests in southern Amazonia. Isolines linking cells of similar composition crossed major Amazonian rivers, suggesting that tree species distributions are not limited by rivers. Even though some areas of relatively sharp species turnover were identified, mostly the tree species composition changed gradually over large extents, which does not support delimiting clear discrete biogeographic regions within Amazonia.

Published
2024
Full Text
View/download PDF

11. Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study

Author

Iurlo, A., primary, Cattaneo, D., additional, Consonni, D., additional, Castagnetti, F., additional, Miggiano, M. C., additional, Binotto, G., additional, Bonifacio, M., additional, Rege-Cambrin, G., additional, Tiribelli, M., additional, Lunghi, F., additional, Gozzini, A., additional, Pregno, P., additional, Abruzzese, E., additional, Capodanno, I., additional, Bucelli, C., additional, Pizzuti, M., additional, Artuso, S., additional, Iezza, M., additional, Scalzulli, E., additional, La Barba, G., additional, Maggi, A., additional, Russo, S., additional, Elena, C., additional, Scortechini, A. R., additional, Tafuri, A., additional, Latagliata, R., additional, Caocci, G., additional, Bocchia, M., additional, Galimberti, S., additional, Luciano, L., additional, Fava, C., additional, Foà, R., additional, Saglio, G., additional, Rosti, G., additional, and Breccia, M., additional

Published
2023
Full Text
View/download PDF

12. Differences among young adults, adults and elderly chronic myeloid leukemia patients

Author

Salvi, F., Pini, M., Leoni, P., Rupoli, S., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Albano, F., Russo Rossi, A., Rambaldi, A., Intermesoli, T., Palandri, F., Testoni, N., Luatti, S., Soverini, S., Iacobucci, I., Bochicchio, M.T., Apolinari, M., Fogli, M., Cervello, I., Capucci, A., Malagola, M., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., Storti, S., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Impera, S., Molica, S., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cavazzini, F., Bosi, A., Santini, V., Capalbo, S.F., Spinosa, G., Pierri, I., Bergamaschi, M., Carella, A.M., Bacigalupo, A., De Blasio, A., Ciccone, F., Di Renzo, N., Musolino, C., Russo, S., Cortelezzi, A., Morra, E., Pungolino, E.M., Luppi, M., Marasca, R., Pogliani, E.M., Gambacorti-Passerini, C., Luciano, L., Ferrara, F., Annunziata, M., Latte, G., Noli, D., Rege-Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Aversa, F., Crugnola, M., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidori, A., Fioritoni, G., Di Lorenzo, R., Vallisa, D., Trabacchi, E., Petrini, M., Galimberti, S., Pizzuti, M., Zaccaria, A., Salvucci, M., Ronco, F., Ielo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Musto, P., De Stefano, V., Sica, S., Latagliata, R., De Fabritiis, P., Trawiska, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Petti, M.C., Pisani, F., Tafuri, A., Montefusco, E., Iuliano, F., Dore, F., Pardini, S., Bocchia, M., Defina, M., Liberati, A.M., Luzzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Gherlinzoni, F., Calistri, E., Fanin, R., Pizzolo, G., Meneghini, V., Rodighiero, F., D'Emilio, A., Castagnetti, F., Gugliotta, G., Baccarani, M., Breccia, M., Specchia, G., Levato, L., Abruzzese, E., Rossi, G., Iurlo, A., Martino, B., Pregno, P., Stagno, F., Cuneo, A., Bonifacio, M., Gobbi, M., Russo, D., Gozzini, A., Tiribelli, M., de Vivo, A., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., and Rosti, G.

Published
2015
Full Text
View/download PDF

14. Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996

Author

Piciocchi, A, Messina, M, Elia, L, Vitale, A, Soddu, S, Testi, A, Chiaretti, S, Mancini, M, Albano, F, Spadano, A, Krampera, M, Bonifacio, M, Cairoli, R, Vetro, C, Colella, F, Ferrara, F, Cimino, G, Bassan, R, Fazi, P, Vignetti, M, Piciocchi A, Messina M, Elia L, Vitale A, Soddu S, Testi AM, Chiaretti S, Mancini M, Albano F, Spadano A, Krampera M, Bonifacio M, Cairoli R, Vetro C, Colella F, Ferrara F, Cimino G, Bassan R, Fazi P, Vignetti M, Piciocchi, A, Messina, M, Elia, L, Vitale, A, Soddu, S, Testi, A, Chiaretti, S, Mancini, M, Albano, F, Spadano, A, Krampera, M, Bonifacio, M, Cairoli, R, Vetro, C, Colella, F, Ferrara, F, Cimino, G, Bassan, R, Fazi, P, Vignetti, M, Piciocchi A, Messina M, Elia L, Vitale A, Soddu S, Testi AM, Chiaretti S, Mancini M, Albano F, Spadano A, Krampera M, Bonifacio M, Cairoli R, Vetro C, Colella F, Ferrara F, Cimino G, Bassan R, Fazi P, and Vignetti M

Published
2021

16. Preservación de la fertilidad en pacientes con diagnóstico de cáncer en etapa infanto-juvenil

Author

Morici, M., Santa Maria, J., Deana, A., Maidana, K., Lioy, G., Noriega, S, Garbini, C., Bonifacio, M., Pantano, V., Moratto, E., Coscia, L., Garabito, M., Sala, J, Mendez, T., Trimboli, I., Forclaz, V., Riccheri, C., Morici, M., Santa Maria, J., Deana, A., Maidana, K., Lioy, G., Noriega, S, Garbini, C., Bonifacio, M., Pantano, V., Moratto, E., Coscia, L., Garabito, M., Sala, J, Mendez, T., Trimboli, I., Forclaz, V., and Riccheri, C.

Abstract

La preservación de la fertilidad es importante para los pacientes sobrevivientes de cáncer. Muchos de ellos mantendrán su potencial reproductivo después de completar con éxito el tratamiento contra el cáncer. Sin embargo, ciertos esquemas terapéuticos como la radiación corporal total, la radiación gonadal y los regímenes de quimioterapia que contienen altas dosis de alquilantes pueden poner a las mujeres en riesgo de insuficiencia ovárica o menopausia prematura y a los hombres en riesgo de azoospermia temporal o permanente. Los métodos establecidos para preservar la fertilidad son la criopreservación de embriones, ovocitos y tejido ovárico en mujeres y la criopreservación de espermatozoides en hombres antes del inicio de la terapia. Proporcionar información sobre el riesgo de infertilidad y las intervenciones posibles para mantener el potencial reproductivo es fundamental para los pacientes pediátricos y adolescentes en el momento del diagnóstico., Fertility preservation is important for childhood and adolescent cancer survivors. Many patients will maintain their reproductive potential after successful completion of cancer treatment. However, total body radiation, gonadal radiation and chemotherapy regimens containing high doses of alkylating agents may put women at risk of ovarian failure or premature menopause and men at risk of temporary or permanent azoospermia. Established methods for preserving fertility are cryopreservation of embryos, oocytes, and ovarian tissue in women and cryopreservation of sperm in men before initiation of therapy. Providing information about the risk of infertility and possible interventions to maintain reproductive potential is critical for pediatric and adolescent patients at the time of diagnosis

Published
2022

17. COVID-19 infection in chronic myeloid leukemia after one year of the pandemic in Italy Campus CML report

Author

Breccia, M, Abruzzese, E, Accurso, V, Attolico, I, Barulli, S, Bergamaschi, M, Binotto, G, Bocchia, M, Bonifacio, M, Caocci, G, Capodanno, I, Castagnetti, F, Cavazzini, F, Crisà, E, Crugnola, M, De Candia, M, Elena, C, Fava, C, Galimberti, S, Gozzini, A, Gugliotta, G, Intermesoli, T, Iurlo, A, La Barba, G, Latagliata, R, Crescenzi, Sl, Levato, L, Loglisci, G, Lucchesi, A, Luciano, L, Lunghi, F, Luzi, D, Malato, A, Miggiano, Mc, Pizzuti, M, Pregno, P, Rapezzi, D, Rege-Cambrin, G, Rosti, G, Russo, S, Sancetta, R, Scortechini, Ar, Sora', Federica, Sportoletti, P, Stagno, F, Tafuri, A, Tiribelli, M, Foà, R, Saglio, G, Sora, Federica (ORCID:0000-0002-9607-5298), Breccia, M, Abruzzese, E, Accurso, V, Attolico, I, Barulli, S, Bergamaschi, M, Binotto, G, Bocchia, M, Bonifacio, M, Caocci, G, Capodanno, I, Castagnetti, F, Cavazzini, F, Crisà, E, Crugnola, M, De Candia, M, Elena, C, Fava, C, Galimberti, S, Gozzini, A, Gugliotta, G, Intermesoli, T, Iurlo, A, La Barba, G, Latagliata, R, Crescenzi, Sl, Levato, L, Loglisci, G, Lucchesi, A, Luciano, L, Lunghi, F, Luzi, D, Malato, A, Miggiano, Mc, Pizzuti, M, Pregno, P, Rapezzi, D, Rege-Cambrin, G, Rosti, G, Russo, S, Sancetta, R, Scortechini, Ar, Sora', Federica, Sportoletti, P, Stagno, F, Tafuri, A, Tiribelli, M, Foà, R, Saglio, G, and Sora, Federica (ORCID:0000-0002-9607-5298)

Abstract

Limited information is available on the impact of the COVID-19 pandemic on the management of chronic myeloid leukaemia (CML). The Campus CML network collected retrospective information on 8 665 CML patients followed at 46 centres throughout Italy during the pandemic between February 2020 and January 2021. Within this cohort, we recorded 217 SARS-CoV-2-positive patients (2·5%). Most patients (57%) were diagnosed as having SARS-CoV-2 infection during the second peak of the pandemic (September 2020 to January 2021). The majority (35%) was aged between 50 and 65 years with a male prevalence (73%). Fifty-six percent of patients presented concomitant comorbidities. The median time from CML diagnosis to SARS-CoV-2 infection was six years (three months to 18 years). Twenty-one patients (9·6%) required hospitalization without the need of respiratory assistance, 18 (8·2%) were hospitalized for respiratory assistance, 8 (3·6%) were admitted to an intensive care unit, while 170 (78%) were only quarantined. Twenty-three percent of patients discontinued tyrosine kinase inhibitor (TKI) therapy during the infection. Twelve patients died due to COVID-19 with a mortality rate of 5·5% in the positive cohort and of 0·13% in the whole cohort. We could also document sequelae caused by the SARS-CoV-2 infection and an impact of the pandemic on the overall management of CML patients.

Published
2022

18. COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report

Author

Chiaretti, S., Bonifacio, M., Agrippino, R., Giglio, F., Annunziata, M., Curti, A., Del Principe, M. I., Salutari, P., Sciume, M., Delia, M., Armenio, M., Mancini, V., Mule, A., Grimaldi, F., Rege-Cambrin, G., Santoro, L., Lussana, F., Chiusolo, Patrizia, Pasciolla, C., Scattolin, A. M., Cerrano, M., Ciccone, M., Defina, M., Forghieri, F., Mazzone, C., Piccini, M., Ferrara, F., Pizzolo, G., Foa, R., Chiusolo P. (ORCID:0000-0002-1355-1587), Chiaretti, S., Bonifacio, M., Agrippino, R., Giglio, F., Annunziata, M., Curti, A., Del Principe, M. I., Salutari, P., Sciume, M., Delia, M., Armenio, M., Mancini, V., Mule, A., Grimaldi, F., Rege-Cambrin, G., Santoro, L., Lussana, F., Chiusolo, Patrizia, Pasciolla, C., Scattolin, A. M., Cerrano, M., Ciccone, M., Defina, M., Forghieri, F., Mazzone, C., Piccini, M., Ferrara, F., Pizzolo, G., Foa, R., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

N/A

Published
2022

19. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study

Author

Cerrano, M., Bonifacio, M., Olivi, M., Curti, A., Malagola, M., Dargenio, M., Scattolin, A. M., Papayannidis, C., Forghieri, F., Gurrieri, C., Tanasi, I., Zappasodi, P., Starza, R. L., Fracchiolla, N. S., Chiusolo, Patrizia, Giaccone, L., Del Principe, M. I., Giglio, F., Defina, M., Favre, C., Rizzari, C., Castella, B., Pizzolo, G., Ferrara, F., Chiaretti, S., Foa, R., Chiusolo P. (ORCID:0000-0002-1355-1587), Cerrano, M., Bonifacio, M., Olivi, M., Curti, A., Malagola, M., Dargenio, M., Scattolin, A. M., Papayannidis, C., Forghieri, F., Gurrieri, C., Tanasi, I., Zappasodi, P., Starza, R. L., Fracchiolla, N. S., Chiusolo, Patrizia, Giaccone, L., Del Principe, M. I., Giglio, F., Defina, M., Favre, C., Rizzari, C., Castella, B., Pizzolo, G., Ferrara, F., Chiaretti, S., Foa, R., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

n/a

Published
2022

20. S113: NATIONAL PEGASPARGASE-MODIFIED RISK-ORIENTED PROGRAM FOR PHILADELPHIA-NEGATIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA (PH− ALL/LL). GIMEMA LAL 1913 FINAL RESULTS.

Author

Bassan, R., primary, Chiaretti, S., additional, Della Starza, I., additional, Spinelli, O., additional, Santoro, A., additional, Elia, L., additional, De Propris, M. S., additional, Scattolin, A. M., additional, Paoloni, F., additional, Messina, M., additional, Audisio, E., additional, Marbello, L., additional, Borlenghi, E., additional, Zappasodi, P., additional, Vetro, C., additional, Martinelli, G., additional, Mattei, D., additional, Fracchiolla, N., additional, Bocchia, M., additional, De Fabritiis, P., additional, Bonifacio, M., additional, Candoni, A., additional, Cassibba, V., additional, Di Bartolomeo, P., additional, Latte, G., additional, Trappolini, S., additional, Guarini, A., additional, Vitale, A., additional, Fazi, P., additional, Vignetti, M., additional, Rambaldi, A., additional, and Foà, R., additional

Published
2022
Full Text
View/download PDF

21. S156: INTERNATIONAL, PROSPECTIVE STUDY COMPARING NILOTINIB VERSUS IMATINIB WITH EARLY SWITCH TO NILOTINIB TO OBTAIN SUSTAINED TREATMENT-FREE REMISSION IN PATIENTS WITH WITH CHRONIC MYELOID LEUKEMIA

Author

Pane, F., primary, Castagnetti, F., additional, Luciano, L., additional, Russo Rossi, A., additional, Abruzzese, E., additional, Bassan, R., additional, Binotto, G., additional, Caocci, G., additional, Cimino, G., additional, Fazi, P., additional, Gozzini, A., additional, Lunghi, M., additional, Marasca, R., additional, Martino, B., additional, Bonifacio, M., additional, Cavazzini, F., additional, Paoloni, F., additional, Saglio, G., additional, Sica, S., additional, Tafuri, A., additional, Vallisa, D., additional, Vignetti, M., additional, Westerweel, P., additional, Rosti, G., additional, and Breccia, M., additional

Published
2022
Full Text
View/download PDF

22. P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME

Author

Palandri, F., primary, Bartoletti, D., additional, Breccia, M., additional, Auteri, G., additional, Elli, E. M., additional, Trawinska, M. M., additional, Polverelli, N., additional, Tiribelli, M., additional, Benevolo, G., additional, Iurlo, A., additional, Tieghi, A., additional, Heidel, F. H., additional, Caocci, G., additional, Beggiato, E., additional, Binotto, G., additional, Cavazzini, F., additional, Miglino, M., additional, Bosi, C., additional, Crugnola, M., additional, Bocchia, M., additional, Martino, B., additional, Pugliese, N., additional, Romagnoli, A. D., additional, Mazzoni, C., additional, Scaffidi, L., additional, Isidori, A., additional, Cattaneo, D., additional, Krampera, M., additional, Pane, F., additional, Cilloni, D., additional, Semenzato, G., additional, Lemoli, R. M., additional, Cuneo, A., additional, Abruzzese, E., additional, Vianelli, N., additional, Cavo, M., additional, Bonifacio, M., additional, and Palumbo, G. A., additional

Published
2022
Full Text
View/download PDF

23. P698: BOSUTINIB DOSE OPTIMIZATION IN THE SECOND-LINE TREATMENT OF ELDERLY CML PATIENTS: EXTENDED 3-YEAR FOLLOW-UP AND FINAL RESULTS OF THE BEST STUDY

Author

Castagnetti, F., primary, Bocchia, M., additional, Abruzzese, E., additional, Capodanno, I., additional, Bonifacio, M., additional, Rege Cambrin, G., additional, Crugnola, M., additional, Binotto, G., additional, Elena, C., additional, Lucchesi, A., additional, Bergamaschi, M., additional, Albano, F., additional, Luciano, L., additional, Sorà, F., additional, Lunghi, F., additional, Stagno, F., additional, Cerrano, M., additional, Iurlo, A., additional, Scortechini, A. R., additional, Leonetti Crescenzi, S., additional, Spadano, R., additional, Trabacchi, E., additional, Lunghi, M., additional, Spinosa, G., additional, Ferrero, D., additional, Rapezzi, D., additional, Ladetto, M., additional, Nocilli, L., additional, Gugliotta, G., additional, Iezza, M., additional, Cavo, M., additional, Saglio, G., additional, Pane, F., additional, and Rosti, G., additional

Published
2022
Full Text
View/download PDF

24. P353: FORTY MONTHS UPDATE OF THE GIMEMA LAL2116 (D-ALBA) PROTOCOL AND ANCILLARY LAL2217 STUDY FOR NEWLY DIAGNOSED ADULT PH+ ALL

Author

Chiaretti, S., primary, Bassan, R., additional, Vitale, A., additional, Elia, L., additional, Piciocchi, A., additional, Viero, P., additional, Ferrara, F., additional, Lunghi, M., additional, Fabbiano, F., additional, Bonifacio, M., additional, Fracchiolla, N., additional, Di Bartolomeo, P., additional, Fazi, P., additional, De Propris, M. S., additional, Vignetti, M., additional, Guarini, A., additional, Rambaldi, A., additional, and Foà, R., additional

Published
2022
Full Text
View/download PDF

25. P1709: FERTILITY PRESERVATION FOR YOUNG ADULT ACUTE LYMPHOBLASTIC LEUKEMIAS IN ITALY: A CAMPUS ALL SURVEY.

Author

Giglio, F., primary, Bruno, A., additional, Dargenio, M., additional, Cerrano, M., additional, Del Principe, M. I., additional, Forghieri, F., additional, Fumagalli, M., additional, Guolo, F., additional, Imovilli, A., additional, Lunghi, M., additional, Mazzone, C., additional, Papayannidis, C., additional, Pasciolla, C., additional, Trappolini, S., additional, Lazzarotto, D., additional, Bonifacio, M., additional, Candoni, A., additional, Ciceri, F., additional, Pizzolo, G., additional, Vitale, A., additional, and Foà, R., additional

Published
2022
Full Text
View/download PDF

26. P357: MULTICENTER RETROSPECTIVE ANALYSIS OF CLINICAL OUTCOME OF ADULT PATIENS WITH MIXED-PHENOTYPE ACUTE LEUKEMIA (MPAL) DIAGNOSED AND TREATED IN THE LAST TEN YEARS. A CAMPUS-ALL STUDY.

Author

Lazzarotto, D., primary, Tanasi, I., additional, Vitale, A., additional, Piccini, M., additional, Dargenio, M., additional, Giglio, F., additional, Forghieri, F., additional, Fracchiolla, N., additional, Cerrano, M., additional, Todisco, E., additional, Papayannidis, C., additional, Leoncin, M., additional, Defina, M., additional, Guolo, F., additional, Pasciolla, C., additional, Delia, M., additional, Chiusolo, P., additional, Mulè, A., additional, Candoni, A., additional, Bonifacio, M., additional, Pizzolo, G., additional, and Foà, R., additional

Published
2022
Full Text
View/download PDF

27. P1708: PREGNANCIES IN YOUNG ADULTS WITH A HISTORY OF ACUTE LYMPHOBLASTIC LEUKEMIA IN ITALY. A CAMPUS ALL SURVEY.

Author

Giglio, F., primary, Bruno, A., additional, Papayannidis, C., additional, Dargenio, M., additional, Cerrano, M., additional, Forghieri, F., additional, Fumagalli, M., additional, Lunghi, M., additional, Annunziata, M., additional, Bonifacio, M., additional, Ferrara, F., additional, Ciceri, F., additional, Pizzolo, G., additional, Vitale, A., additional, and Foà, R., additional

Published
2022
Full Text
View/download PDF

28. P1009: PREDICTORS OF HOSPITALIZATION AND SEVERE OUTCOMES IN PATIENTS WITH MPN AND COVID-19

Author

Barbui, T., primary, Carobbio, A., additional, Masciulli, A., additional, Iurlo, A., additional, Sobas, M. A., additional, Elli, E. M., additional, Rumi, E., additional, De Stefano, V., additional, Lunghi, F., additional, Marchetti, M., additional, Daffini, R., additional, Gasior Kabat, M., additional, Cuevas, B., additional, Fox, M. L., additional, Andrade Campos, M. M., additional, Palandri, F., additional, Guglielmelli, P., additional, Benevolo, G., additional, Harrison, C., additional, Foncillas, M. A., additional, Bonifacio, M., additional, Alvarez-Larran, A., additional, Kiladjian, J.-J., additional, Bolanos Calderon, E., additional, Patriarca, A., additional, Quiroz Cervantes, K. S., additional, Griesshammer, M., additional, Garcia-Gutierrez, V., additional, Marin Sanchez, A., additional, Magro Mazo, E., additional, Ruggeri, M., additional, Hernandez-Boluda, J. C., additional, Osorio, S., additional, Carreno-Tarragona, G., additional, Sagues Serrano, M., additional, Kusec, R., additional, Navas Elorza, B., additional, Angona, A., additional, Xicoy Cirici, B., additional, Lopez Abadia, E., additional, Koschmieder, S., additional, Cichocka, E., additional, Kulikowska de Nałęcz, A., additional, Bellini, M., additional, Cattaneo, D., additional, Bucelli, C., additional, Cavalca, F., additional, Borsani, O., additional, Betti, S., additional, Curto-Garcia, N., additional, Carbonell, S., additional, Benajiba, L., additional, Rambaldi, A., additional, and Vannucchi, A. M., additional

Published
2022
Full Text
View/download PDF

29. P1706: CLINICAL UTILITY OF ONLINE MONITORING OF PATIENT-REPORTED SYMPTOMS IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN REAL-LIFE PRACTICE

Author

Efficace, F., primary, Cottone, F., additional, Yanez, B., additional, Castagnetti, F., additional, Caocci, G., additional, Bonifacio, M., additional, Patriarca, A., additional, Capodanno, I., additional, Miggiano, M. C., additional, Tiribelli, M., additional, Breccia, M., additional, Luciano, L., additional, Giai, V., additional, Iurlo, A., additional, Abruzzese, E., additional, Fava, C., additional, Rosti, G., additional, Cortes, J., additional, Kota, V., additional, Vignetti, M., additional, and Cella, D., additional

Published
2022
Full Text
View/download PDF

30. P1011: PREDICTORS OF COVID-19 DISEASE AND SURVIVAL TO COVID-19 IN MPN PATIENTS TREATED WITH RUXOLITINIB

Author

Palandri, F., primary, Bartoletti, D., additional, Elli, E. M., additional, Auteri, G., additional, Bonifacio, M., additional, Benevolo, G., additional, Heidel, F., additional, Trawinska, M. M., additional, Rossi, E., additional, Bosi, C., additional, Tieghi, A., additional, Tiribelli, M., additional, Iurlo, A., additional, Polverelli, N., additional, Caocci, G., additional, Binotto, G., additional, Cavazzini, F., additional, Beggiato, E., additional, Cilloni, D., additional, Tatarelli, C., additional, Mendicino, F., additional, Miglino, M., additional, Bocchia, M., additional, Crugnola, M., additional, Mazzoni, C., additional, Romagnoli, A. D., additional, Rindone, G., additional, Ceglie, S., additional, D’Addio, A., additional, Santoni, E., additional, Cattaneo, D., additional, Lemoli, R. M., additional, Krampera, M., additional, Cuneo, A., additional, Semenzato, G., additional, Latagliata, R., additional, Abruzzese, E., additional, Vianelli, N., additional, Cavo, M., additional, Andriani, A., additional, De Stefano, V., additional, Palumbo, G., additional, and Breccia, M., additional

Published
2022
Full Text
View/download PDF

31. P993: SETD2 IS A BONA FIDE TUMOR SUPPRESSOR IN SYSTEMIC MASTOCYTOSIS

Author

Mancini, M., primary, Monaldi, C., additional, De Santis, S., additional, Papayannidis, C., additional, Rondoni, M., additional, Sartor, C., additional, Bruno, S., additional, Curti, A., additional, Zanotti, R., additional, Bonifacio, M., additional, Scaffidi, L., additional, Pagano, L., additional, Criscuolo, M., additional, Ciceri, F., additional, Elena, C., additional, Tosi, P., additional, Valent, P., additional, Cavo, M., additional, and Soverini, S., additional

Published
2022
Full Text
View/download PDF

33. Determinants of early triage for hospitalization in MPN patients with COVID-19

Author

Barbui T, Carobbio A, Ghirardi A, Iurlo A, Sobas M, Elli E, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox M, Andrade-Campos M, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas M, Bonifacio M, Alvarez-Larran A, Kiladjian J, Calderon E, Patriarca A, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Marin Sanchez A, Mazo E, Carli G, Hernandez-Boluda J, Osorio S, Carreno-Tarragona G, Serrano M, Kusec R, Elorza B, Angona A, Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, de Nalecz A, Cavalca F, Borsani O, Betti S, Bellini M, Curto-Garcia N, Rambaldi A, and Vannucchi A

Published
2022

34. INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph1 acute lymphoblastic leukemia

Author

Martinelli, G., Papayannidis, C., Piciocchi, A., Robustelli, V., Soverini, S., Terragna, C., Marconi, G., Lemoli, R. M., Guolo, F., Fornaro, A., Lunghi, M., de Fabritiis, P., Candoni, A., Selleri, C., Simonetti, F., Bocchia, M., Vitale, A., Frison, L., Tedeschi, A., Cuneo, A., Bonifacio, M., Martelli, M. P., D'Ardia, S., Trappolini, S., Tosi, P., Galieni, P., Fabbiano, F., Abbenante, M. C., Granier, M., Zhu, Z., Wang, M., Sartor, C., Paolini, S., Cavo, M., Foa, R., Fazi, P., Vignetti, M., and Baccarani, M.

Published
2022

35. Carboxymethyl cellulose-based hydrogel film combined with berberine as an innovative tool for chronic wound management

Author

Cometa, S., Licini, C., Bonifacio, M. A., Mastrorilli, P., Mattioli-Belmonte, M., and De Giglio, E.

Subjects
Keratinocytes, Polymers and Plastics, Berberine, Cell Survival, carboxymethyl cellulose sodium salt (PubChem CID: 6328154), gallium nitrate (PubChem CID: 61635), Biocompatible Materials, bentonite clay (PubChem CID: 72941614), Antioxidants, boric acid (PubChem CID: 7628), Spectroscopy, Fourier Transform Infrared, Materials Chemistry, Humans, CMC-based film, Berberine Hydrochloride (PubChem CID: 12456), Chronic wound, 2,2-diphenyl-1-picrylhydrazylhydrate (DPPH) (PubChem CID: 2735032), 2,2′- azino-bis(ethylbenztiazolinone-6-sulfonic) acid (ABTS) (PubChem CID: 5815211), Fibroblasts, Topical delivery, hydroxyethyl cellulose (PubChem CID: 4327536) Acetylated distarch phosphate (PubChem SID: 24832109), lysozyme (PubChem CID 16130991), Bandages, Carboxymethylcellulose Sodium, Hydrogels, Oxidative Stress, Temperature, Wound Healing, Spectroscopy, 2′- azino-bis(ethylbenztiazolinone-6-sulfonic) acid (ABTS) (PubChem CID: 5815211), Organic Chemistry, 2-diphenyl-1-picrylhydrazylhydrate (DPPH) (PubChem CID: 2735032), Fourier Transform Infrared
Abstract

Polysaccharide-based hydrogels are achieving remarkable performances in chronic wounds treatment. In this work, a carboxymethyl cellulose-based hydrogel film was developed to support skin repair. The hydrogel was loaded with berberine, a polyphenolic molecule endowing antioxidant and cytoprotective features. The film was physico-chemically characterized and in vitro tested on keratinocytes and fibroblasts subjected to oxidative stress. The biocomposite showed high thermal stability (onset decomposition temperature 245 °C) and significant fluid uptake performances, both in free conditions (up to 6510%) and under external pressure (up to 3400%). Moreover, it was able to control oxidative stress and inflammation markers involved in wound chronicity. Keratinocytes hyperproliferation, features that normally hamper injury restoration, was reduced of 25%. Our results showed that the combination of berberine and hydrogel provides a synergic improvement of the material properties. The biocomposite represents a promising candidate for dermatological applications against oxidative stress at the chronic wound site, promoting the healing process.

Published
2022

36. Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996

Author

Piciocchi, A., Messina, M., Elia, L., Vitale, A., Soddu, S., Testi, A. M., Chiaretti, S., Mancini, M., Albano, F., Spadano, A., Krampera, M., Bonifacio, M., Cairoli, R., Vetro, C., Colella, F., Ferrara, F., Cimino, G., Bassan, R., Fazi, P., Vignetti, M., Piciocchi, A, Messina, M, Elia, L, Vitale, A, Soddu, S, Testi, A, Chiaretti, S, Mancini, M, Albano, F, Spadano, A, Krampera, M, Bonifacio, M, Cairoli, R, Vetro, C, Colella, F, Ferrara, F, Cimino, G, Bassan, R, Fazi, P, and Vignetti, M

Subjects
Adult, Male, Oncogene Proteins, Fusion, Prognosi, DNA-Binding Protein, bcr-abl, Fusion Proteins, bcr-abl, Histone-Lysine N-Methyltransferase, MED/15 - MALATTIE DEL SANGUE, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, DNA-binding proteins, adult, female, fusion proteins, bcr-abl, humans, male, Female, Survival Analysi, Transcriptional Elongation Factors, fusion proteins, Myeloid-Lymphoid Leukemia Protein, Human
Published
2021

38. Families on the Streets: Placemaking in an Urban Heritage Site in Cebu City, the Philippines.

Author

Amper Jr., Bonifacio M.

Subjects
*HISTORIC sites, *HOMELESS persons, *PUBLIC spaces, *SOCIAL services, *SOCIAL networks
Abstract

Streets are public spaces where people pass through in going from one place to another. As such, streets are not supposed to be dwelling places. However, rapid urbanization has ushered in problems on housing, livelihood, and basic social facilities and services, giving rise to informal settlements and street living in cities. In Cebu City (a highly urbanized city in Central Philippines), displacement from urban slums as well as, lack of livelihood options have pushed some people to dwell on the streets and sidewalks in sites most visited by foreign and local tourists. Through street ethnography, this research uncovers how street dwellers in a heritage site in downtown Cebu City came to live and make a living here. The findings point to the fact that street dwellers have socially constructed and purposely transformed heritage spaces into places where they do their daily domestic routines as well as livelihood activities, in order to survive. This article posits that placemaking by these street dwellers in this heritage site is a process from entering and integrating into the place, appropriating specific spaces into places with meanings for them, building and maintaining social networks, contesting notions of the place, and developing a street culture over time. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

43. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview

Author

Baccarani, M, Castagnetti, F, Gugliotta, G, Rosti, G, Soverini, S, Albeer, A, Pfirrmann, M, Bekadja, Ma, Entasoltan, B, Nachi, M, Elghandour, A, El Sorady, M, Abdelfattah, R, El Nahass, Y, Samra, M, Azzazi, M, Elsobki, E, Moussa, M, Fahmy, O, Mattar, M, Shehata, Azmy, Se, (Azmy, E, 9 ), Emad), Bolarinwa, (Bolarinwa, Ra, ( 10 ), Rahman A., Eid, (Eid, S, Samir)( 11, ), Khelif, (Khelif, A, Abderrhaim)( 11, ), Hached, (Hached, F, Farhat)( 11, ), Menif, (Menif, S, Samia)( 12, ), Rahman, (Rahman, H, Hafizur)( 13, ), Huang, (Huang, Xj, Xiaojun)(, 14, 15, ), Jiang, (Jiang, Q, Qian)(, 14, (Ye, Yx, Yuanxin)( 16, ), Zhu, (Zhu, Hl, Huanling)( 16, ), Chen, (Chen, Sn, Suning)( 17, ), Varma, (Varma, N, Neelam)( 18, ), Ganesan, (Ganesan, P, Prasanth)( 19, ), Gundeti, (Gundeti, S, Sadashivudu)( 20, ), Malhotra, (Malhotra, H, Hemant)( 21, ), Radhakrishnan, (Radhakrishnan, Vs, ( 22 ), Vivek S., Kumar, (Kumar, L, Lalit)( 23, ), Sharawat, (Sharawat, Sk, Surender Kumar)( 23, ), Seth, (Seth, T, Tulika)( 24, ), Ausekar, (Ausekar, Bv, ( 25 ), B. V., Balasubramanian, (Balasubramanian, P, Poonkuzhali)( 26, ), Poopak, (Poopak, B, Behzad)(, 27, 28, ), Inokuchi, (Inokuchi, K, Koiti)( 29, ), Kim, (Kim, Dw, Dong-Wook)( 30, ), Kindi, Al, S (Al Kindi, Salam)( 31, ), Mirasol, (Mirasol, A, Angelina)( 32, ), Qari, (Qari, M, Mohammed)( 33, ), Goh, (Goh, Yt, Yeow Tee)( 34, ), Shih, (Shih, Ly, Lee-Yung)(, 35, 36, ), Branford, (Branford, S, Susan)(, 37, 38, ), Lion, (Lion, T, Thomas)( 39, ), Valent, (Valent, P, Peter)( 40, ), Burgstaller, (Burgstaller, S, Sonja)( 41, ), Thaler, (Thaler, J, Joseph)( 41, ), Labar, (Labar, B, Boris)( 42, ), Zadro, (Zadro, R, Renata)( 42, ), Mayer, (Mayer, J, Jiri)(, 43, 44, ), Zackova, (Zackova, D, Daniela)(, 43, Faber, (Faber, E, Edgar)( 45, ), Pallisgaard, (Pallisgaard, N, Niels)( 46, ), Xavier-Mahon, (Xavier-Mahon, F, Francois)( 47, ), Lippert, (Lippert, E, Eric)( 48, ), Cayuela, (Cayuela, Jm, Jean Michel)( 49, ), Rea, (Rea, D, Delphine)( 49, ), Millot, (Millot, F, Frederic)( 50, ), Suttorp, (Suttorp, M, Meinolf)( 51, ), Hochhaus, (Hochhaus, A, Andreas)( 52, ), Niederwieser, (Niederwieser, D, Dietger)( 53, ), Saussele, (Saussele, S, Susanne)( 54, ), Haferlach, (Haferlach, T, Torsten)( 55, ), Jeromine, (Jeromine, S, Sabine)( 55, ), Panayiotidis, (Panayiotidis, P, Panayiotis)(, 56, 57, ), Conneally, (Conneally, E, Eibhlin)( 58, ), Langabeer, (Langabeer, S, Steve)( 58, ), Nagler, (Nagler, A, Arnon)(, 59, 60, ), Rupoli, (Rupoli, S, Serena)( 61, ), Santoro, (Santoro, N, Nicola)( 62, ), Albano, (Albano, F, Francesco)( 63, ), Castagnetti, (Castagnetti, F, Fausto), Ottaviani, (Ottaviani, E, Emanuela)(, 64, 65, ), Rambaldi, (Rambaldi, A, Alessandro)(, 66, 67, ), Stagno, (Stagno, F, Fabio)( 68, ), Molica, (Molica, S, Stefano)( 69, ), Biagiotti, (Biagiotti, C, Caterina)( 70, ), Scappini, (Scappini, B, Barbara)( 70, ), Lemoli, (Lemoli, R, Roberto)( 71, ), Iurlo, (Iurlo, A, Alessandra)(, 72, 73, ), Pungolino, (Pungolino, E, Ester)( 74, ), Menna, (Menna, G, Giuseppe), Pane, (Pane, F, Fabrizio)( 76, ), Gottardi, (Gottardi, E, Enrico)(, 77, 78, ), Rege-Cambrin, (Rege-Cambrin, G, Giovanna)(, 77, Binotto, (Binotto, G, Gianni)( 79, ), Putti, (Putti, Mc, Maria Caterina)( 80, ), Falzetti, (Falzetti, F, Franca)( 81, ), Visani, (Visani, G, Giuseppe)( 82, ), Galimberti, (Galimberti, S, Sara)( 83, ), Musto, (Musto, P, Pellegrino)( 84, ), Abruzzese, (Abruzzese, E, Elisabetta)( 85, ), Breccia, (Breccia, M, Massimo)( 86, ), Giona, (Giona, F, Fiorina)( 86, ), Chiusolo, (Chiusolo, P, Patrizia)( 87, ), Sica, (Sica, S, Simona)( 87, ), Fava, (Fava, C, Carmen)( 88, ), Ferrero, (Ferrero, D, Dario)( 88, ), Tiribelli, (Tiribelli, M, Mario)( 89, ), Bonifacio, (Bonifacio, M, Massimiliano)( 90, ), Griskevicius, (Griskevicius, L, Laimonas)( 91, ), Musteata, (Musteata, V, Vasile)( 92, ), Janssen, (Janssen, J, Jeroen)( 93, ), Prejzner, (Prejzner, W, Witold)( 94, ), Sacha, (Sacha, T, Tomasz)( 95, ), Waclaw, (Waclaw, J, Joanna)( 95, ), Almeida, (Almeida, Am, Antonio Medina)( 96, ), Kulikov, (Kulikov, S, Sergei)( 97, ), Turkina, (Turkina, A, Anna)( 97, ), Bogdanovic, (Bogdanovic, A, Andrija)( 98, ), Zupan, (Zupan, I, Irena)( 99, ), Marce, (Marce, S, Silvia)( 100, ), Cervantes, (Cervantes, F, Francisco)( 101, ), Steegmann, (Steegmann, Jl, Juan Luis)( 102, ), Kotlyarchuk, (Kotlyarchuk, K, Konstyantyn)( 103, ), Milner, (Milner, Bj, ( 104 ), Benedict J., Rose, (Rose, S, Susan)( 105, ), Clench, (Clench, T, Tim)( 106, ), Waits, (Waits, P, Paula)( 107, ), Austin, (Austin, S, Steve)( 108, ), Wickham, (Wickham, C, Caroline)( 109, ), Clark, (Clark, R, Richard)( 110, ), Apperley, (Apperley, J, Jane), Claudiani, (Claudiani, S, Simone)( 111, ), Foroni, (Foroni, L, Letizia)( 111, ), Szydlo, (Szydlo, R, Richard)( 111, ), Burt, (Burt, E, Emma)( 112, ), Bescoby, (Bescoby, R, Ruth)( 113, ), Cork, (Cork, L, Leanne)( 113, ), O'Brien, (O'Brien, S, Stephen)( 113, ), Green, (Green, B, Bethaney)( 114, ), Hawtree, (Hawtree, S, Sarah)( 114, ), Watson, (Watson, M, Mark)( 114, ), Bengio, (Bengio, Rm, Raquel Maria)( 115, ), Larripa, (Larripa, I, Irene)( 115, ), Pavlovsky, (Pavlovsky, C, Carolina)( 116, ), Moiraghi, (Moiraghi, B, Beatriz)( 117, ), Pinna, De, CAR (Requiao de Pinna, Cristiane Almeida)( 118, ), Magalhaes, GHR (Romani Magalhaes, Gustavo Henrique)( 119, ), Pagnano, (Pagnano, K, Katia)( 120, ), Funke, (Funke, V, Vaneuza)( 121, ), Tavares, (Tavares, Rs, Renato Sampaio)( 122, ), Prado, (Prado, A, Adriana)( 123, ), Azevedo, (Azevedo, Aa, Alita Andrade)( 124, ), Fogliatto, (Fogliatto, L, Laura)( 125, ), Bonecker, (Bonecker, S, Simone)( 126, ), Centrone, (Centrone, R, Renato)( 127, ), Moellman, (Moellman, A, Artur)( 128, ), Conchon, (Conchon, M, Monika)( 130, ), Centurion, (Centurion, Me, Maria Elida)( 131, ), (Prado, Ai, Ana-Ines)( 132, ), Lopez, (Lopez, Jl, ( 133 ), J. L., Petruzziello, (Petruzziello, F, Fara)( 75, ), Bendit, (Bendit, I, Israel), Baccarani M., Castagnetti F., Gugliotta G., Rosti G., Soverini S., Albeer A., and Pfirrmann M.

Subjects
Male, 0301 basic medicine, Cancer Research, bcr-abl, Fusion Proteins, bcr-abl, Global Health, 0302 clinical medicine, hemic and lymphatic diseases, 80 and over, Odds Ratio, Prevalence, Age Factor, Chronic, Young adult, Child, MOLECULAR RESPONSE, Leukemic, Aged, 80 and over, Leukemia, Hematology, Gene Expression Regulation, Leukemic, CHRONIC MYELOGENOUS LEUKEMIA, Age Factors, Myeloid leukemia, Middle Aged, Oncology, Child, Preschool, 030220 oncology & carcinogenesis, Female, Life Sciences & Biomedicine, Human, Adult, Transcriptional Activation, medicine.medical_specialty, Adolescent, Immunology, IMATINIB MESYLATE, DENDRITIC CELLS, CML PATIENTS, Young Adult, 03 medical and health sciences, Myelogenous, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Internal medicine, medicine, Humans, 1112 Oncology and Carcinogenesis, BCR/ABL TRANSCRIPT, Preschool, CYTOGENETIC RESPONSE, Aged, Science & Technology, CHRONIC-PHASE, business.industry, Infant, Newborn, Fusion Proteins, ABL FUSION PROTEINS, P190 BCR-ABL, Infant, 1103 Clinical Sciences, Odds ratio, Newborn, medicine.disease, International BCR-ABL Study Group, Settore MED/15 - MALATTIE DEL SANGUE, 030104 developmental biology, Imatinib mesylate, Gene Expression Regulation, BCR-ABL Positive, business, Chronic myelogenous leukemia
Abstract

There are different BCR-ABL1 fusion genes that are translated into proteins that are different from each other, yet all leukemogenic, causing chronic myeloid leukemia (CML) or acute lymphoblastic leukemia. Their frequency has never been systematically investigated. In a series of 45503 newly diagnosed CML patients reported from 45 countries, it was found that the proportion of e13a2 (also known as b2a2) and of e14a2 (also known as b3a2), including the cases co-expressing e14a2 and e13a2, was 37.9% and 62.1%, respectively. The proportion of these two transcripts was correlated with gender, e13a2 being more frequent in males (39.2%) than in females (36.2%), was correlated with age, decreasing from 39.6% in children and adolescents down to 31.6% in patients ≥ 80 years old, and was not constant worldwide. Other, rare transcripts were reported in 666/34561 patients (1.93%). The proportion of rare transcripts was associatedwith gender (2.27% in females and 1.69% in males) and with age (from 1.79% in children and adolescents up to 3.84% in patients ≥ 80 years old). These data show that the differences in proportion are not by chance. This is important, as the transcript type is a variable that is suspected to be of prognostic importance for response to treatment, outcome of treatment, and rate of treatment-free remission.

Published
2019
Full Text
View/download PDF

45. Differences among young adults, adults and elderly chronic myeloid leukemia patients

Author

Castagnetti, F., Gugliotta, G., Baccarani, M., Breccia, M., Specchia, G., Levato, L., Abruzzese, E., Rossi, G., Iurlo, A., Martino, B., Pregno, P., Stagno, F., Cuneo, A., Bonifacio, M., Gobbi, M., Russo, D., Gozzini, A., Tiribelli, M., de Vivo, A., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Salvi, F., Pini, M., Leoni, P., Rupoli, S., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Albano, F., Russo Rossi, A., Rambaldi, A., Intermesoli, T., Palandri, F., Testoni, N., Luatti, S., Soverini, S., Iacobucci, I., Bochicchio, MT., Apolinari, M., Fogli, M., Cervello, I., Capucci, A., Malagola, M., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., Storti, S., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Impera, S., Molica, S., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cavazzini, F., Bosi, A., Santini, V., Capalbo, SF., Spinosa, G., Pierri, I., Bergamaschi, M., Carella, AM., Bacigalupo, A., De Blasio, A., Ciccone, F., Di Renzo, N., Musolino, C., Russo, S., Cortelezzi, A., Morra, E., Pungolino, EM., Luppi, M., Marasca, R., Pogliani, EM., Gambacorti-Passerini, C., Luciano, L., Ferrara, F., Annunziata, M., Latte, G., Noli, D., Rege-Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Aversa, F., Crugnola, M., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidori, A., Fioritoni, G., Di Lorenzo, R., Vallisa, D., Trabacchi, E., Petrini, M., Galimberti, S., Pizzuti, M., Zaccaria, A., Salvucci, M., Ronco, F., Ielo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Musto, P., De Stefano, V., Sica, S., Latagliata, R., De Fabritiis, P., Trawiska, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Petti, MC., Pisani, F., Tafuri, A., Montefusco, E., Iuliano, F., Dore, F., Pardini, S., Bocchia, M., Defina, M., Liberati, AM., Luzzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Gherlinzoni, F., Calistri, E., Fanin, R., Pizzolo, G., Meneghini, V., Rodighiero, F., and DʼEmilio, A.

Published
2015
Full Text
View/download PDF

46. Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia

Author

Efficace, F., Iurlo, A., Patriarca, A., Stagno, F., Bee, P.C., Ector, G.I.C.G., Capodanno, I., Elena, C., Bonifacio, M., Blijlevens, N.M.A., Caocci, G., Wan, C., Abruzzese, E., Breccia, M., Cottone, F., Okumura, I., Oerlemans, S., Cascavilla, N., Albano, F., Kota, V., Sztankay, M., Miggiano, M.C., Saussele, S., Renzo, N. Di, Sorà, F., Castagnetti, F., Baccarani, M., Vignetti, M., Rosti, G., Efficace, F., Iurlo, A., Patriarca, A., Stagno, F., Bee, P.C., Ector, G.I.C.G., Capodanno, I., Elena, C., Bonifacio, M., Blijlevens, N.M.A., Caocci, G., Wan, C., Abruzzese, E., Breccia, M., Cottone, F., Okumura, I., Oerlemans, S., Cascavilla, N., Albano, F., Kota, V., Sztankay, M., Miggiano, M.C., Saussele, S., Renzo, N. Di, Sorà, F., Castagnetti, F., Baccarani, M., Vignetti, M., and Rosti, G.

Abstract

Item does not contain fulltext, Health-related quality of life (HRQOL) assessment is important to facilitate decisions in the current treatment landscape of chronic myeloid leukemia (CML). Therefore, the availability of a validated HRQOL questionnaire, specifically developed for CML patients treated with tyrosine kinase inhibitors (TKIs), may enhance quality of research in this area. We performed an international study including 782 CML patients to assess the validity of the EORTC QLQ-CML 24 questionnaire, and to generate HRQOL reference values to facilitate interpretation of results in future studies. Internal consistency, assessed with Cronbach's alpha coefficients, ranged from 0.66 to 0.83. In the confirmatory factor analysis, all standardized factor loadings exceeded the threshold of 0.40 (range 0.49-0.97), confirming the hypothesized scale structure. Reference values stratified by age and sex were also generated. Our findings support the use of the EORTC QLQ-CML 24, in conjunction with the EORTC QLQ-C30, as a valuable measure to assess HRQOL in CML patients.

Published
2021

47. next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome -positive acute lymphoblastic leukemia

Author

Soverini, S, Martelli, M, Bavaro, L, De Benedittis, C, Papayannidis, C, Sartor, C, Sora', Federica, Albano, F, Galimberti, S, Abruzzese, E, Annunziata, M, Russo, S, Stulle, M, Imovilli, A, Bonifacio, M, Maino, E, Stagno, F, Basilico, Cm, Borlenghi, E, Fozza, C, Mignone, F, Minari, R, Stella, S, Baccarani, M, Cavo, M, Martinelli, G, Sora, Federica (ORCID:0000-0002-9607-5298), Soverini, S, Martelli, M, Bavaro, L, De Benedittis, C, Papayannidis, C, Sartor, C, Sora', Federica, Albano, F, Galimberti, S, Abruzzese, E, Annunziata, M, Russo, S, Stulle, M, Imovilli, A, Bonifacio, M, Maino, E, Stagno, F, Basilico, Cm, Borlenghi, E, Fozza, C, Mignone, F, Minari, R, Stella, S, Baccarani, M, Cavo, M, Martinelli, G, and Sora, Federica (ORCID:0000-0002-9607-5298)

Abstract

BCR-ABL1 kinase domain mutation testing in tyrosine kinase inhibitor (TKI)-resistant Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) patients is routinely performed by Sanger sequencing (SS). Recently, next-generation sequencing (NGS)-based approaches have been developed that afford greater sensitivity and straightforward discrimination between compound and polyclonal mutations. We performed a study to compare the results of SS and NGS in a consecutive cohort of 171 Ph+ ALL patients. At diagnosis, 0/44 and 3/44 patients were positive for mutations by SS and NGS respectively. Out of 47 patients with haematologic resistance, 45 had mutations according to both methods, but in 25 patients NGS revealed additional mutations undetectable by SS. Out of 80 patients in complete haematologic response but with BCR-ABL1 ≥0·1%, 28 (35%) and 52 (65%) were positive by SS and NGS respectively. Moreover, in 12 patients positive by SS, NGS detected additional mutations. NGS resolved clonal complexity in 34 patients with multiple mutations at the same or different codons and identified 35 compound mutations. Our study demonstrates that, in Ph+ ALL on TKI therapy, NGS enables more accurate assessment of mutation status both in patients who fail therapy and in patients with minimal residual disease above 0·1%.

Published
2021

49. Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey

Author

Breccia, M., Abruzzese, E., Bocchia, M., Bonifacio, M., Castagnetti, F., Fava, C., Galimberti, S., Gozzini, A., Gugliotta, G., Iurlo, A., Latagliata, R., Luciano, L., Pregno, P., Rege-Cambrin, G., Rosti, G., Stagno, F., Tiribelli, M., Foa, R., Saglio, G., Mariacristina, M. M., Isabella, C., Vincenzo, A., Federica, S., Debora, L., Mario, A., Immacolata, A., Alessandra, M., Rosaria, S., Chiara, E., Sara, B., Rita, S. A., Sabrina, L. -C., Agostino, T., Francesco, C., Giovanni, C., Alessandro, L., Davide, R., Michele, P., Gianni, B., Tamara, I., Alessandro, M., Elena, C., Monica, C., Mariella, D. A., Germana, B., Francesca, L., Iolanda -Donatella, V., Grazia, S., Luca, F., Sabina, R., Gaetano, L. B., Breccia M., Abruzzese E., Bocchia M., Bonifacio M., Castagnetti F., Fava C., Galimberti S., Gozzini A., Gugliotta G., Iurlo A., Latagliata R., Luciano L., Pregno P., Rege-Cambrin G., Rosti G., Stagno F., Tiribelli M., Foa R., Saglio G., MariaCristina M.M., Isabella C., Vincenzo A., Federica S., Debora L., Mario A., Immacolata A., Alessandra M., Rosaria S., Chiara E., Sara B., Rita S.A., Sabrina L.-C., Agostino T., Francesco C., Giovanni C., Alessandro L., Davide R., Michele P., Gianni B., Tamara I., Alessandro M., Elena C., Monica C., Mariella D.A., Germana B., Francesca L., Iolanda -Donatella V., Grazia S., Luca F., Sabina R., and Gaetano L.B.

Subjects
Cancer Research, 2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Pneumonia, Viral, Protein Kinase Inhibitor, Time-to-Treatment, Betacoronavirus, Myelogenous, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Surveys and Questionnaires, Correspondence, Pandemic, Surveys and Questionnaire, COVID-19, Coronavirus Infections, Disease Management, Humans, Infection Control, Italy, Pandemics, Practice Guidelines as Topic, Protein Kinase Inhibitors, SARS-CoV-2, Telemedicine, Medicine, Viral, Chronic, Disease management (health), Chronic myeloid leukaemia, Leukemia, Betacoronaviru, Coronavirus Infection, business.industry, Myeloid leukemia, Pneumonia, Hematology, medicine.disease, Oncology, Family medicine, BCR-ABL Positive, business, Haematological diseases, Human
Abstract

No abstract available.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results